Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

Newomics Inc. Places Its 100th Mass Spectrometry Front-end System

Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.

The system is made up of an ion source integrated with breakthrough silicon microfluidic chips including M3 emitters and MEA chips. System models include the MnESI system with M3 emitters launched in November 2020, and the DuoESI system with M3 emitters and MEA chips launched in June 2022.

System performance has been validated by 8 customers' peer-reviewed papers, published in key industry journals like Analytical Chemistry and Journal of Chromatography A.

The success of the Newomics system has led to international co-marketing partnerships with Thermo Fisher Scientific and Bruker and collaborations with Agilent, Shimadzu, and Waters.

Founder and CEO, Daojing Wang, Ph.D., says he is especially pleased with how customers have embraced the Newomics platform solutions: "We set out to tackle the key challenges in mass spectrometry, including sensitivity, robustness, and throughput. With the product developments by our dedicated team, and through collaborations with global mass spec industry leaders, we have delivered unique mass spec front-end solutions to our customers. We will continue to fulfill customer needs and address the challenges in their mass spectrometry workflows in 2023 and beyond."

About Newomics

Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company's products deliver the sensitivity and robustness for superior nanoflow and microflow LC-MS. The plug-and-play MnESI platform (MnESI source + M3 emitter) and DuoESI platform (DuoESI source + M3 emitter + MEA chip) are currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.

These press releases may also interest you

at 13:00
The Canada Revenue Agency (CRA) has resumed efforts to recover taxpayers' debt. One of the tools the CRA uses to recover debt is called offsetting. Offsetting proactively applies tax refunds and benefit payments (such as the GST/HST credit) to tax...

at 07:46
Georgia Power announced today it has achieved another important milestone for the new nuclear units under construction at its Vogtle 3 & 4 nuclear expansion project near Waynesboro, Ga. The generator at Vogtle Unit 3 has generated electricity for the...

at 06:00
GLG Life Tech Corporation ("GLG" or the "Company"), a global leader in the agricultural and commercial development of high-quality zero-calorie natural sweeteners, announced today that it intends to delay the filing of its annual...

31 mar 2023
The Employee Retention Credit (ERC) tax refund program from the Internal Revenue Service (IRS) was designed for small to medium-sized business (SMB) owners that struggled. It could have been financially through a significant decline in gross...

31 mar 2023
Nouveau Monde Graphite Inc. ("NMG" or the "Company") announces today the payment of accrued interests as part of a previously announced private placement. Settlement of accrued interests Upon the approval of the TSX Venture Exchange and the New...

31 mar 2023
The hospice market is estimated to grow by USD 89.07 billion during 2022-2027. However, the growth momentum will progress at a CAGR of 4.11% during the forecast period. The market is segmented by service (nursing services, medical supply services,...

News published on 1 february 2023 at 13:05 and distributed by: